The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Just for clarity, this status has no endorsement of the drug itself, I could be wrong but I really can't see any further upmove on this news. Surprised its moved this far to be honest. Still expect a move back down in the coming weeks.
Orphan drug status gives companies researching cures for rare diseases a seven-year window of tax reductions and the exclusive right to develop a cure for a specific condition. Orphan drug status can be granted for new drugs, already approved drugs, or drugs that are already on the market.
Due to a much smaller patient pool and the higher cost of launching on the market, orphan medicines appear less profitable for the pharmaceutical companies to invest in, as the unit cost is significantly higher, compared to more commonly prescribed drugs.
Orphan drug development takes 15.1 years to go from first patent filing to product launch, 18 percent longer than the average time required for all new drugs, according to the Tufts Center for the Study of Drug Development.
Ade2017
“ A deramper then, like you did on QBT, typical of you to make a comment on a share you want in on a lower SP and missed the boat”
Who’s the deramper, Ade?
averaging up
Gap from 7.5p in July now closed, and should act as a support hopefully.
First stage with this is complete, more to come once they have partnered with US Pharma, it maybe an interesting last two hours of the day potentially when the US Stock Exchange opens at 2.30pm
Now the sellers have read the RNS they can't get back in
Drop the price then go NT
Lucky mr Kight . I am sure it was a 100% just that, luck . ;)
This will bounce shortly
A deramper then, like you did on QBT, typical of you to make a comment on a share you want in on a lower SP and missed the boat
Thought as much. Fearmongering on a board you don't hold a position in, as usual. Go away.
MM's shaking the tree to try to get back all the stock they sold pre-RNS (at a profit to them of course). Now we've got to the level they want to buy again you can't buy more than 100k below 8p. More than that and it's 8.5p+
Here we go again , I wonder what the closing SP will be, the current SP is erratic on IG anything from 26% to 33% increase
Wilfred, Target price on RNS 7.9p or whatever the mm's choose! Actually, it depends on potential big pharma interest but i am hoping we could double the sp given the small mcap.
Boom
RNS out
Just bought in. Target price on RNS?
mm's are playing games here
For the benefit of Mr Kight, there will be an RNS tonight,,,
SP has settled down nicely with a 22.66% rise, lovely increase, makes you wonder what will happen with a positive RNS
Or just on Holiday or stuck at McDonald’s !!!
I think the rns writer is stuck in traffic somewhere!